Vaxcyte/PCVX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Vaxcyte

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Ticker

PCVX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Grant Pickering

Employees

254

Headquarters

San carlos, United States

Vaxcyte Metrics

BasicAdvanced
$7.6B
Market cap
-
P/E ratio
-$4.22
EPS
0.97
Beta
-
Dividend rate
$7.6B
0.968
$82.04
$44.20
644K
17.417
-28.19%
-29.83%
-29.52%
3.852
3.853
-23.41%

What the Analysts think about Vaxcyte

Analyst Ratings

Majority rating from 9 analysts.
Buy

Vaxcyte Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$95M
-47.46%
Profit margin
0.00%
NaN%

Vaxcyte Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 27.27%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.70
-$0.91
-$1.82
-$0.85
-
Expected
-$0.75
-$0.84
-$1.07
-$1.17
-$0.99
Surprise
-6.04%
8.66%
69.78%
-27.27%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Vaxcyte stock?

Vaxcyte (PCVX) has a market cap of $7.6B as of June 20, 2024.

What is the P/E ratio for Vaxcyte stock?

The price to earnings (P/E) ratio for Vaxcyte (PCVX) stock is 0 as of June 20, 2024.

Does Vaxcyte stock pay dividends?

No, Vaxcyte (PCVX) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next Vaxcyte dividend payment date?

Vaxcyte (PCVX) stock does not pay dividends to its shareholders.

What is the beta indicator for Vaxcyte?

Vaxcyte (PCVX) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Vaxcyte stock price target?

The target price for Vaxcyte (PCVX) stock is $103.14, which is NaN% below the current price of $. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Vaxcyte stock

Buy or sell Vaxcyte stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing